Targeting a key pathway in triple negative breast cancer to improve treatment options
NextGen RNAi Delivery to Breast Tumors for Selective mTORC2 Blockade
This study is testing a new treatment for people with triple negative breast cancer that aims to make existing therapies work better by using a special medicine to target a protein that helps cancer cells survive, which could lead to improved outcomes and lower chances of the cancer coming back.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vanderbilt University NIH-funded |
| Lab location | 1 site (Nashville, UNITED STATES) |
| Project ID | NIH-10439746 on NIH RePORTER |
What this research studies
This research focuses on developing a new treatment for patients with triple negative breast cancer (TNBC), a type of cancer known for its poor response to existing therapies. The approach involves creating a specialized nanomedicine that selectively inhibits a specific protein complex (mTORC2) that contributes to cancer cell survival and resistance to chemotherapy. By targeting this pathway, the researchers aim to enhance the effectiveness of treatment and reduce the chances of cancer recurrence. Patients may benefit from this innovative therapy if it proves successful in clinical applications.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with triple negative breast cancer who have limited treatment options and are at risk of recurrence.
Not a fit: Patients with other types of breast cancer or those who do not have triple negative breast cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new targeted therapy for patients with triple negative breast cancer, potentially improving survival rates and treatment outcomes.
How similar studies have performed: While targeting the mTOR pathway has been explored in other contexts, this specific approach to selectively inhibit mTORC2 in TNBC is novel and has not been extensively tested.
Where this research is happening
Nashville, UNITED STATES
- Vanderbilt University — Nashville, United States (Active)
Researchers
- Principal investigator: Duvall, Craig Lewis — Vanderbilt University
- Study coordinator: Duvall, Craig Lewis
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.